CYP2C19 Polymorphism and Platelet Aggregation‐Associated Risks in Atrial Fibrillation Patients Undergoing PCI
Clinical and Translational Science · 2026-06 · 19 (6)
DOI: 10.1111/cts.70598 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Translational Science, online erschienen am 19.05.2026. Verfasst von Diona Gjermeni und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, German…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cytochrome P-450 CYP2C19, Percutaneous Coronary Intervention, Platelet Aggregation. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
CYP2C19 genetic polymorphisms impact the antiplatelet effect of clopidogrel and associate with ischemic and bleeding risk in patients undergoing percutaneous coronary intervention (PCI). This study aimed to evaluate the association of CYP2C19 and platelet reactivity (PR) with these risks, in atrial fibrillation (AF) patients undergoing PCI, treated with an oral anticoagulation (OAC) and clopidogrel. This two‐center prospective cohort study included patients with AF and OAC undergoing PCI. Carriers of ≥ 1 loss‐of‐function (LOF) allele were classified as poor/intermediate metabolizers (PM/IM), whereas carriers of ≥ 1 gain‐of‐function allele without LOF alleles were classified as rapid metabolizers (RM). PR was assessed by thromboelastography (TEG) and/or multiple electrode aggregometry (MEA). The primary outcome included death, MI, or stroke at 6 months ±2 weeks; the secondary outcome consisted of non‐major clinically relevant (NMCR) or major bleeding. Among 283 patients (median age 78 years; 72% male), 73 (26%) were PM/IM, 108 (38%) were NM, and 102 (36%) were RM. PM/IM status was not significantly associated with the primary ischemic outcome (PM/IM: 6 [8.2%] vs. NM + RM: 16 [7.6%], p = 0.869), but any bleeding rates were numerically lower. While there was a trend for association of high platelet reactivity (HPR) with the ischemic outcome (OR 2.005 [95% CI 0.820–4.902], p = 0.127), low platelet reactivity (LPR) was associated with major bleeding (OR 2.646 [95% CI 1.075–6.509], p = 0.034). PM/IM status did not detect an increased ischemic risk but might, however, protect from bleeding risk in AF patients undergoing PCI. HPR might indicate a higher ischemic risk, while LPR was associated with major bleeding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Institute of Human Genetics, Medical Center - University of Freiburg, Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Department of Cardiology, Haemostaseology and Medical Intensive Care, Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.
- European Center for AngioScience (ECAS) and German Center for Cardiovascular Research (DZHK) Partner Site Heidelberg/Mannheim, Mannheim, Germany.
ORCID-Profile: Svenja Rademacher
Zitieren
APA
Gjermeni, D., Szabó, S., Anfang, V., Vetter, H., Juelch, C., Rademacher, S., Li, T., Leggewie, S., Hesselbarth, D., Duerschmied, D., Trenk, D., Westermann, D., & Olivier, C. B. (2026). CYP2C19 Polymorphism and Platelet Aggregation‐Associated Risks in Atrial Fibrillation Patients Undergoing PCI. Clinical and Translational Science, 19(6). https://doi.org/10.1111/cts.70598
Vancouver
Gjermeni D, Szabó S, Anfang V, Vetter H, Juelch C, Rademacher S, et al. CYP2C19 Polymorphism and Platelet Aggregation‐Associated Risks in Atrial Fibrillation Patients Undergoing PCI. Clinical and Translational Science. 2026;19(6). doi:10.1111/cts.70598
BibTeX
@article{Gjermeni2026,
author = {Gjermeni, Diona and Szabó, Sofia and Anfang, Viktoria and Vetter, Hannah and Juelch, Carina and Rademacher, Svenja and Li, Tian and Leggewie, Stefan and Hesselbarth, David and Duerschmied, Daniel and Trenk, Dietmar and Westermann, Dirk and Olivier, Christoph B},
title = {CYP2C19 Polymorphism and Platelet Aggregation‐Associated Risks in Atrial Fibrillation Patients Undergoing PCI},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {6},
doi = {10.1111/cts.70598}
}
EUVIMED